Targeting CD89 on tumor-associated macrophages overcomes resistance to immune checkpoint blockade

Abstract

CD89 BsAbs targeting tumor antigens and TAMs controlled tumor growth in animal models by improving antigen presentation and T-cell infiltration. Our results suggest a general strategy for overcoming resistance to ICB.